| Item Type | Name |
|
Concept
|
Antigens, Differentiation, B-Lymphocyte
|
|
Concept
|
B-Lymphocytes
|
|
Concept
|
HeLa Cells
|
|
Concept
|
T-Lymphocytes, Helper-Inducer
|
|
Concept
|
Hematopoietic Stem Cells
|
|
Concept
|
Killer Cells, Natural
|
|
Concept
|
Lymphocytes
|
|
Concept
|
Plasma Cells
|
|
Concept
|
T-Lymphocytes
|
|
Concept
|
CD4-Positive T-Lymphocytes
|
|
Concept
|
Endothelial Cells
|
|
Concept
|
B-Lymphocyte Subsets
|
|
Concept
|
B-Cell Activating Factor
|
|
Concept
|
HEK293 Cells
|
|
Concept
|
Precursor Cells, B-Lymphoid
|
|
Concept
|
Th17 Cells
|
|
Concept
|
Cells, Cultured
|
|
Concept
|
Foam Cells
|
|
Academic Article
|
Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.
|
|
Academic Article
|
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
|
|
Academic Article
|
Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus.
|
|
Academic Article
|
Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity.
|
|
Academic Article
|
Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients.
|
|
Academic Article
|
Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells.
|
|
Academic Article
|
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
|
|
Academic Article
|
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
|
|
Academic Article
|
Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production.
|
|
Academic Article
|
Epigenetic Reprogramming in Naive CD4+ T Cells Favoring T Cell Activation and Non-Th1 Effector T Cell Immune Response as an Early Event in Lupus Flares.
|
|
Academic Article
|
Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls.
|
|
Academic Article
|
Immunologic findings precede rapid lupus flare after transient steroid therapy.
|
|
Academic Article
|
BLyS antagonists and peptide tolerance induction.
|
|
Academic Article
|
Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease.
|
|
Academic Article
|
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
|
|
Academic Article
|
Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups.
|
|
Academic Article
|
Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK.
|
|
Academic Article
|
Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus.
|
|
Academic Article
|
DNA methylation patterns in naïve CD4+ T cells identify epigenetic susceptibility loci for malar rash and discoid rash in systemic lupus erythematosus.
|
|
Academic Article
|
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.
|
|
Academic Article
|
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials.
|
|
Academic Article
|
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index.
|
|
Academic Article
|
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.
|
|
Academic Article
|
What causes the antiphospholipid syndrome?
|
|
Academic Article
|
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
|
|
Academic Article
|
B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.
|
|
Academic Article
|
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
|
|
Academic Article
|
Trans-ancestral studies fine map the SLE-susceptibility locus TNFSF4.
|
|
Academic Article
|
Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells.
|
|
Academic Article
|
Genetic association of CD247 (CD3?) with SLE in a large-scale multiethnic study.
|
|
Academic Article
|
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
|
|
Academic Article
|
SR proteins are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes.
|
|
Academic Article
|
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus.
|
|
Academic Article
|
MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus.
|
|
Academic Article
|
Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity.
|
|
Academic Article
|
Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.
|
|
Academic Article
|
Disease activity in systemic lupus erythematosus correlates with expression of the transcription factor AT-rich-interactive domain 3A.
|
|
Academic Article
|
Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura.
|
|
Academic Article
|
Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity.
|
|
Academic Article
|
Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
|
|
Academic Article
|
Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role for genetic factors in the lupus-associated DNA methylation signature.
|